{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:27:09Z","timestamp":1783067229219,"version":"3.54.6"},"reference-count":55,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ekir.2025.08.046","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:47:53Z","timestamp":1756946873000},"page":"3918-3936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Rituximab as Adjunctive Therapy to Immunosuppressive Agents in Adult Primary Focal Segmental Glomerulosclerosis"],"prefix":"10.1016","volume":"10","author":[{"given":"Osama Nady","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa Ibrahim","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen Mohammed","family":"Mohammed Elsaghir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimaa","family":"Abdelrazek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aml","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek Mahmoud","family":"Senosy Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan M.H.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman Ahmed","family":"Abd Rabou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem Y.","family":"Abdelazeem Elgarhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Khalifa","family":"Mohamed Mahdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ahmed","family":"Abdelsamie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar M.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermeen Dahi","family":"Mohammed Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabeh Khairy","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Fathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.08.046_bib1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.046_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ekir.2021.10.017","article-title":"Efficacy of rituximab in treatment-resistant focal segmental glomerulosclerosis with elevated soluble urokinase-type plasminogen activator receptor and activation of podocyte \u03b23 integrin","volume":"7","author":"Hladunewich","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.08.046_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2150451","article-title":"Immunologic changes implicated in the pathogenesis of focal segmental glomerulosclerosis","volume":"2016","author":"Kronbichler","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ekir.2025.08.046_bib6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4192578","article-title":"Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades","volume":"2016","author":"Beer","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ekir.2025.08.046_bib8","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.mayocp.2021.01.037","article-title":"Identification of genetic causes of focal segmental glomerulosclerosis increases with proper patient selection","volume":"96","author":"Miao","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2025.08.046_bib9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1681\/ASN.0000000000000076","article-title":"A clinical workflow for cost-saving high-rate diagnosis of genetic kidney diseases","volume":"16","author":"Becherucci","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib11","first-page":"1670","article-title":"Rituximab as maintenance treatment for systemic lupus erythematosus: a multicenter observational study of 147 patients","volume":"71","author":"Cassia","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.08.046_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ekir.2025.08.046_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.ekir.2025.08.046_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102671","article-title":"Rituximab in adult minimal change disease and focal segmental glomerulosclerosis\u2014what is known and what is still unknown?","volume":"19","author":"Gauckler","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.08.046_bib15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ckj\/sfy067","article-title":"Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome","volume":"12","author":"Cortazar","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.08.046_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/nep.13717","article-title":"Rituximab in maintaining remission in adults with podocytopathy","volume":"25","author":"Ramachandran","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2025.08.046_bib18","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.ekir.2022.05.024","article-title":"The role of rituximab in primary focal segmental glomerular sclerosis of the adult","volume":"7","author":"Tedesco","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.08.046_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12882-025-04066-7","article-title":"Serum midkine level and its association with subclinical coronary artery calcification and carotid atherosclerosis in chronic kidney disease","volume":"26","author":"Mohamed","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib20","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2025.08.046_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1369\/0022155416649579","article-title":"A buffered alcohol-based fixative for histomorphologic and molecular applications","volume":"64","author":"Perry","year":"2016","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.ekir.2025.08.046_bib22","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.ki.5001903","article-title":"Cellular focal segmental glomerulosclerosis: clinical and pathologic features","volume":"70","author":"Stokes","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.046_bib23","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1038\/s41598-023-32576-7","article-title":"Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS","volume":"13","author":"Osterholt","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2025.08.046_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2023.1181076","article-title":"A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design","volume":"3","author":"Rheault","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib25","article-title":"WCN25-156 rituximab maintenance therapy is effective in maintaining remission in steroid dependent and frequent relapsing adult nephrotic syndrome","volume":"10","author":"Feder","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.08.046_bib26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1681\/ASN.0000000520","article-title":"Long-term outcomes of rituximab-treated adult patients with podocytopathies","volume":"36","author":"Gauckler","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib29","first-page":"1647","article-title":"Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial","volume":"37","author":"Wheeler","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib30","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib31","first-page":"789","article-title":"Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis","volume":"37","author":"Allinovi","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ekir.2025.08.046_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.789713","article-title":"Therapies for membranous nephropathy: a tale from the old and new millennia","volume":"13","author":"Scolari","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.08.046_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","article-title":"Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes","volume":"97","author":"Chan","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.046_bib35","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/ckj\/sfac207","article-title":"Focal segmental glomerular sclerosis can be effectively treated using an intensive B-cell depletion therapy","volume":"16","author":"Roccatello","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.08.046_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","article-title":"Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis","volume":"21","author":"Hansrivijit","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib37","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","article-title":"Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab","volume":"32","author":"Kamei","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.kint.2021.09.014","article-title":"Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients","volume":"100","author":"Bertrand","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.046_bib39","first-page":"307","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome: a systematic review","volume":"7","author":"Azarfar","year":"2018","journal-title":"Iran J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.08.046_bib41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12882-025-04035-0","article-title":"Long-term efficacy of rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome","volume":"26","author":"Feder","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib42","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2147\/DDDT.S302257","article-title":"Consolidation treatment and long-term prognosis of rituximab in minimal change disease and focal segmental glomerular sclerosis","volume":"15","author":"Lin","year":"2021","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.ekir.2025.08.046_bib43","first-page":"1734","article-title":"Evolution of nephritic-associated focal segmental glomerulosclerosis: a clinicopathologic study","volume":"50","author":"Howie","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.046_bib44","first-page":"590","article-title":"Different clinicopathological types of segmental sclerosing glomerular lesions in adults","volume":"8","author":"Howie","year":"1993","journal-title":"Histopathology"},{"key":"10.1016\/j.ekir.2025.08.046_bib45","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.2215\/CJN.13091215","article-title":"Renal survival in patients with collapsing compared with not otherwise specified FSGS","volume":"11","author":"Laurin","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/nep.13757","article-title":"Rituximab in treatment of collapsing FSGS\u2014a case series","volume":"26","author":"Girimaji","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2025.08.046_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00467-018-4166-1","article-title":"Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children","volume":"35","author":"Kamei","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib48","first-page":"1225","article-title":"Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults","volume":"28","author":"Takei","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib49","first-page":"1083","article-title":"Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2014follow-up after CD19 recovery","volume":"27","author":"Sellier-Leclerc","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib50","first-page":"1321","article-title":"Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children","volume":"24","author":"Kamei","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib51","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10157-020-02002-7","article-title":"Clinical characteristics of patients with early relapse during B-cell depletion after rituximab treatment for complicated steroid-dependent nephrotic syndrome","volume":"25","author":"Fujinaga","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib52","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.08.046_bib53","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib54","first-page":"588","article-title":"Efficacy and safety of rituximab in children with steroid-dependent or frequently relapsing nephrotic syndrome: a meta-analysis of randomized controlled trials","volume":"21","author":"Luo","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.08.046_bib55","first-page":"60","article-title":"Rituximab experience in children with nephrotic syndrome: what have we observed differently","volume":"55","author":"Giri\u015fgen","year":"2020","journal-title":"Turk Pediatri Ars"},{"key":"10.1016\/j.ekir.2025.08.046_bib56","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","article-title":"Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"14","author":"Xue","year":"2020","journal-title":"Clin Kidney J"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925005546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925005546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:52:33Z","timestamp":1783025553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925005546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2468024925005546"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.08.046","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Rituximab as Adjunctive Therapy to Immunosuppressive Agents in Adult Primary Focal Segmental Glomerulosclerosis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.08.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.09.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}